Ranolazine is Contraindicated at eGFR 22 mL/min
Do not prescribe ranolazine to this patient. With an eGFR of 22 mL/min, this patient has severe renal impairment (CKD stage 4), and ranolazine should not be used when GFR is <30 mL/min/1.73 m² 1.
Why Ranolazine Cannot Be Used
The FDA drug label explicitly documents that a pharmacokinetic study in patients with severe renal impairment (CrCL <30 mL/min) was terminated early when 2 of 4 subjects developed acute renal failure after receiving ranolazine 500 mg twice daily for only 5 days, followed by dose escalation 2. One patient required hemodialysis, while the other two improved only after drug discontinuation 2.
Key Pharmacokinetic Problems in Severe Renal Impairment:
- Ranolazine is primarily excreted by the kidney 1
- Plasma levels increase 40-50% even in mild to moderate renal impairment 2
- The drug undergoes extensive hepatic metabolism but relies on renal clearance 1
- Accumulation leads to marked increases in creatinine, BUN, and potassium 2
Clinical Evidence Supporting This Contraindication
Expert consensus guidelines from Nature Reviews Cardiology (2018) explicitly state: "Ranolazine and trimetazidine should not be prescribed when glomerular filtration rate is <30 ml/min/1.73 m²" 1. The guidelines emphasize that these drugs "should not be used in patients with chronic stable angina and chronic kidney disease, because they carry the risk of further complications" 1.
A case report further illustrates the danger: an 81-year-old woman with renal impairment developed severe neurologic adverse effects (dysarthria, dysmetria, hallucinations, tremors) just 48 hours after a dose increase, which resolved only after ranolazine discontinuation 3. The authors specifically recommend avoiding doses greater than 500 mg twice daily in patients with CrCL <30 mL/minute 3.
Alternative Antianginal Options
For this patient with severe renal impairment, consider:
- Beta-blockers (no contraindication in CKD) 1
- Calcium channel blockers (dihydropyridines or non-dihydropyridines) 1
- Long-acting nitrates 1
- Ivabradine (if heart rate reduction needed) 1
These alternatives have no specific contraindications related to renal function and can safely manage chronic stable angina in patients with eGFR <30 mL/min 1.
Critical Pitfall to Avoid
Do not attempt dose reduction as a workaround. Even the lowest dose (500 mg twice daily) caused acute renal failure in the FDA study of severe renal impairment 2. The 40-50% increase in drug exposure occurs across all degrees of renal impairment, making any dose potentially dangerous 2.